sentence
stringlengths 27
1.01k
| drug1
stringlengths 2
46
| drug2
stringlengths 2
63
| relation
stringclasses 5
values | source_file
stringclasses 566
values | sentence_id
stringlengths 17
21
| pair_id
stringlengths 20
26
|
|---|---|---|---|---|---|---|
Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.
|
Cholestyramine
|
phenylbutazone
|
MECHANISM
|
Cholestyramine_ddi.xml
|
DDI-DrugBank.d566.s0
|
DDI-DrugBank.d566.s0.p1
|
Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
|
glucocorticoids
|
heparin
|
NONE
|
Levothyroxine_ddi.xml
|
DDI-DrugBank.d411.s4
|
DDI-DrugBank.d411.s4.p390
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
methylphenidate
|
trimethoprim
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p1157
|
Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
|
Probenecid
|
theophylline
|
MECHANISM
|
Cidofovir_ddi.xml
|
DDI-DrugBank.d260.s0
|
DDI-DrugBank.d260.s0.p27
|
ZEBETA should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently.
|
ZEBETA
|
calcium antagonists
|
ADVISE
|
Bisoprolol_ddi.xml
|
DDI-DrugBank.d476.s3
|
DDI-DrugBank.d476.s3.p1
|
Concomitant administration of Mefloquine and other related compounds (eg, quinine, quinidine and chloroquine) may produce electrocardiographic abnormalities and increase the risk of convulsions.
|
Mefloquine
|
quinidine
|
EFFECT
|
Mefloquine_ddi.xml
|
DDI-DrugBank.d220.s5
|
DDI-DrugBank.d220.s5.p1
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
EQUETROTM
|
triazolam
|
MECHANISM
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p40
|
cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide).
|
cimetidine
|
flecainide
|
NONE
|
Amitriptyline_ddi.xml
|
DDI-DrugBank.d99.s7
|
DDI-DrugBank.d99.s7.p4
|
Use with Allopurinol: The principal pathway for detoxification of azathioprine is inhibited by allopurinol.
|
azathioprine
|
allopurinol
|
MECHANISM
|
Azathioprine_ddi.xml
|
DDI-DrugBank.d233.s0
|
DDI-DrugBank.d233.s0.p2
|
In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.
|
dexamethasone
|
CANCIDAS
|
MECHANISM
|
Caspofungin_ddi.xml
|
DDI-DrugBank.d350.s12
|
DDI-DrugBank.d350.s12.p16
|
Blunting of the antihypertensive effect of beta-adrenoceptor blocking agents by non-steroidal antiinflammatory drugs including INDOCIN has been reported.
|
beta-adrenoceptor blocking agents
|
non-steroidal antiinflammatory drugs
|
EFFECT
|
Indomethacin_ddi.xml
|
DDI-DrugBank.d82.s33
|
DDI-DrugBank.d82.s33.p0
|
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.
|
ciprofloxacin
|
antacids
|
MECHANISM
|
Ciprofloxacin_ddi.xml
|
DDI-DrugBank.d123.s8
|
DDI-DrugBank.d123.s8.p12
|
Patients taking coumarin-derivative anticoagulants concomitantly with capecitabine should be monitored regularly for alterations in their coagulation parameters (PT or INR).
|
coumarin-derivative anticoagulants
|
capecitabine
|
ADVISE
|
Capecitabine_ddi.xml
|
DDI-DrugBank.d88.s4
|
DDI-DrugBank.d88.s4.p0
|
Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;magnesium salts;procainamide;and quinidine.
|
TRACRIUM
|
isoflurane
|
EFFECT
|
Atracurium_ddi.xml
|
DDI-DrugBank.d469.s7
|
DDI-DrugBank.d469.s7.p1
|
Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
|
itraconazole
|
nicotinamide
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s4
|
DDI-DrugBank.d94.s4.p264
|
Consider additive sedative effects and confusional states to emerge, if chlorprothixene is given with benzodiazepines or barbituates.
|
chlorprothixene
|
barbituates
|
EFFECT
|
Chlorprothixene_ddi.xml
|
DDI-DrugBank.d503.s5
|
DDI-DrugBank.d503.s5.p1
|
Aspirin should be used cautiously in conjunction with cortico-steroids in patients suffering from hypopro-thrombinemia.
|
Aspirin
|
cortico-steroids
|
ADVISE
|
Cortisone acetate_ddi.xml
|
DDI-DrugBank.d487.s6
|
DDI-DrugBank.d487.s6.p0
|
Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and ciprofloxacin when administered concomitantly with an intravenous opiate such as morphine.
|
opiate
|
morphine
|
NONE
|
11210403.xml
|
DDI-MedLine.d124.s1
|
DDI-MedLine.d124.s1.p5
|
Strong inducers of cytochrome P450 enzymes (i.e. carbamazepine, phenytoin and phenobarbital) have been shown to decrease the plasma levels of MHD (29-40%).
|
carbamazepine
|
phenytoin
|
NONE
|
Oxcarbazepine_ddi.xml
|
DDI-DrugBank.d307.s38
|
DDI-DrugBank.d307.s38.p0
|
Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;magnesium salts;procainamide;and quinidine.
|
TRACRIUM
|
lithium
|
EFFECT
|
Atracurium_ddi.xml
|
DDI-DrugBank.d469.s7
|
DDI-DrugBank.d469.s7.p6
|
Mercaptopurine/Azathioprine: Allopurinol inhibits the enzymatic oxidation of mercaptopurine and azathioprine to 6-thiouric acid.
|
Allopurinol
|
mercaptopurine
|
MECHANISM
|
Allopurinol_ddi.xml
|
DDI-DrugBank.d413.s2
|
DDI-DrugBank.d413.s2.p9
|
Although not studied with alosetron, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid, procainamide, and hydralazine.
|
alosetron
|
isoniazid
|
EFFECT
|
Alosetron_ddi.xml
|
DDI-DrugBank.d364.s15
|
DDI-DrugBank.d364.s15.p0
|
Naproxen: The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.
|
diflunisal
|
naproxen
|
MECHANISM
|
Diflunisal_ddi.xml
|
DDI-DrugBank.d132.s27
|
DDI-DrugBank.d132.s27.p4
|
Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
|
Protease Inhibitors
|
cisapride
|
NONE
|
Cisapride_ddi.xml
|
DDI-DrugBank.d237.s12
|
DDI-DrugBank.d237.s12.p3
|
The CNS effects of butalbital may be enhanced by monoamine oxidase (MAO) inhibitors.
|
butalbital
|
monoamine oxidase (MAO) inhibitors
|
EFFECT
|
Butalbital_ddi.xml
|
DDI-DrugBank.d559.s0
|
DDI-DrugBank.d559.s0.p0
|
Limited data in patients receiving known enzyme inducers ( phenytoin, phenobarbital, carbamazepine ) indicate only a 30% increase in the rate of flecainide elimination.
|
phenytoin
|
flecainide
|
MECHANISM
|
Flecainide_ddi.xml
|
DDI-DrugBank.d87.s13
|
DDI-DrugBank.d87.s13.p2
|
Although the magnitude of changes in diazepam plasma exposure when coadministered with valdecoxib were not sufficient to warrant dosage adjustments, patients may experience enhanced sedative side effects caused by increased exposure of diazepam under this circumstance.
|
valdecoxib
|
diazepam
|
EFFECT
|
Valdecoxib_ddi.xml
|
DDI-DrugBank.d328.s49
|
DDI-DrugBank.d328.s49.p2
|
Concomitant use of bromocriptine mesylate with other ergot alkaloids is not recommended.
|
bromocriptine mesylate
|
ergot alkaloids
|
ADVISE
|
Bromocriptine_ddi.xml
|
DDI-DrugBank.d272.s3
|
DDI-DrugBank.d272.s3.p0
|
The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.
|
chlorpromazine
|
amitriptyline
|
EFFECT
|
Chlorpromazine_ddi.xml
|
DDI-DrugBank.d86.s0
|
DDI-DrugBank.d86.s0.p8
|
Bacteriostatic Antibiotics: Chloramphenicol, erythromycins, sulfonamides, or tetracyclines may interfere with the bactericidal effect of penicillins.
|
Chloramphenicol
|
penicillins
|
EFFECT
|
Ampicillin_ddi.xml
|
DDI-DrugBank.d211.s2
|
DDI-DrugBank.d211.s2.p8
|
ketoconazole), macrolide antibiotics (e.g. erythromycin), and HIV protease inhibitors (e.g. ritonavir, indinavir and saquinavir) should have their dose of SUBUTEX or SUBOXONE adjusted.
|
macrolide antibiotics
|
saquinavir
|
NONE
|
Buprenorphine_ddi.xml
|
DDI-DrugBank.d380.s2
|
DDI-DrugBank.d380.s2.p12
|
Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
|
glucocorticoids
|
thiazide diuretics
|
NONE
|
Levothyroxine_ddi.xml
|
DDI-DrugBank.d411.s4
|
DDI-DrugBank.d411.s4.p407
|
Tissue culture and animal studies indicate that ELSPAR can diminish or abolish the effect of methotrexate on malignant cells.14 This effect on methotrexate activity persists as long as plasma asparagine levels are suppressed.
|
ELSPAR
|
methotrexate
|
EFFECT
|
Asparaginase_ddi.xml
|
DDI-DrugBank.d21.s0
|
DDI-DrugBank.d21.s0.p0
|
Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.
|
ketamine
|
fentayl
|
NONE
|
1167743.xml
|
DDI-MedLine.d23.s2
|
DDI-MedLine.d23.s2.p10
|
When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because pralidoxime may potentiate the effect of atropine.
|
pralidoxime
|
atropine
|
EFFECT
|
Atropine_ddi.xml
|
DDI-DrugBank.d222.s0
|
DDI-DrugBank.d222.s0.p9
|
Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.
|
Levo-Dromoran
|
tranquilizers
|
EFFECT
|
Levorphanol_ddi.xml
|
DDI-DrugBank.d257.s0
|
DDI-DrugBank.d257.s0.p9
|
This small decrease in excretion of gabapentin by cimetidine is not expected to be of clinical importance.
|
gabapentin
|
cimetidine
|
MECHANISM
|
Gabapentin_ddi.xml
|
DDI-DrugBank.d438.s31
|
DDI-DrugBank.d438.s31.p0
|
Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and theophylline did not affect the pharmacokinetics of TIKOSYN.
|
aluminum hydroxide
|
theophylline
|
NONE
|
Dofetilide_ddi.xml
|
DDI-DrugBank.d558.s32
|
DDI-DrugBank.d558.s32.p61
|
Carbamazepine - Combined administration of racemic citalopram (40 mg/day for 14 days) and carbamazepine (titrated to 400 mg/day for 35 days) did not significantly affect the pharmacokinetics of carbamazepine, a CYP3A4 substrate.
|
Carbamazepine
|
carbamazepine
|
NONE
|
Escitalopram_ddi.xml
|
DDI-DrugBank.d568.s22
|
DDI-DrugBank.d568.s22.p2
|
Leucovorin may enhance the toxicity of 5-fluorouracil.
|
Leucovorin
|
5-fluorouracil
|
EFFECT
|
Leucovorin_ddi.xml
|
DDI-DrugBank.d151.s3
|
DDI-DrugBank.d151.s3.p0
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
chlorpropamide
|
fenoprofen
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p460
|
The mean clearances of dofetilide were 16% and 15% lower in patients on thiazide diuretics and inhibitors of tubular organic cation transport, respectively.
|
dofetilide
|
thiazide diuretics
|
MECHANISM
|
Dofetilide_ddi.xml
|
DDI-DrugBank.d558.s37
|
DDI-DrugBank.d558.s37.p0
|
- Cholestyramine and colestipol resins: Cholestytamine and colestipol resins have the potential of binding thiazide diuretics and reducing diuretic absorption from the gastrointestinal tract
|
colestipol
|
thiazide diuretics
|
MECHANISM
|
Chlorothiazide_ddi.xml
|
DDI-DrugBank.d46.s7
|
DDI-DrugBank.d46.s7.p23
|
Antibiotics: In vitro and/or in vivo data show that clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
|
Antibiotics
|
clarithromycin
|
NONE
|
Cisapride_ddi.xml
|
DDI-DrugBank.d237.s2
|
DDI-DrugBank.d237.s2.p0
|
Phenytoin, nicotine, and rifampin may decrease Clozapine plasma levels, resulting in a decrease in effectiveness of a previously effective Clozapine dose.
|
Phenytoin
|
Clozapine
|
MECHANISM
|
Clozapine_ddi.xml
|
DDI-DrugBank.d480.s15
|
DDI-DrugBank.d480.s15.p2
|
plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well.
|
tricyclic antidepressants
|
barbiturates
|
MECHANISM
|
Clomipramine_ddi.xml
|
DDI-DrugBank.d238.s6
|
DDI-DrugBank.d238.s6.p3
|
Thus, when NSAIDs and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.
|
NSAIDs
|
lithium
|
ADVISE
|
Mefenamic acid_ddi.xml
|
DDI-DrugBank.d400.s12
|
DDI-DrugBank.d400.s12.p0
|
Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
|
sulfonylureas
|
coumarins
|
EFFECT
|
Glipizide_ddi.xml
|
DDI-DrugBank.d225.s0
|
DDI-DrugBank.d225.s0.p6
|
In patients taking diclofenac and lithium concomitantly, lithium toxicity may develop.
|
diclofenac
|
lithium
|
EFFECT
|
Diclofenac_ddi.xml
|
DDI-DrugBank.d249.s9
|
DDI-DrugBank.d249.s9.p0
|
Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.
|
phenytoin
|
calcitriol
|
MECHANISM
|
Calcidiol_ddi.xml
|
DDI-DrugBank.d98.s2
|
DDI-DrugBank.d98.s2.p11
|
Both ibogaine and 18-MC block morphine-induced and nicotine-induced dopamine release in the nucleus accumbens;
|
ibogaine
|
nicotine
|
EFFECT
|
11085336.xml
|
DDI-MedLine.d110.s6
|
DDI-MedLine.d110.s6.p2
|
In general, these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride, including anti-arrhythmic agents such as quinidine and procainamide, cardiac glycosides and tricyclic anti-depressants.
|
quinidine
|
procainamide
|
NONE
|
Bepridil_ddi.xml
|
DDI-DrugBank.d137.s9
|
DDI-DrugBank.d137.s9.p9
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
anticoagulant
|
methyldopa
|
EFFECT
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p26
|
Nevertheless, the possibility of additive negative inotropic effects of beta blockers and flecainide should be recognized.
|
beta blockers
|
flecainide
|
EFFECT
|
Flecainide_ddi.xml
|
DDI-DrugBank.d87.s8
|
DDI-DrugBank.d87.s8.p0
|
Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
|
bupropion
|
fluoxetine
|
ADVISE
|
Bupropion_ddi.xml
|
DDI-DrugBank.d5.s17
|
DDI-DrugBank.d5.s17.p5
|
Phenobarbital: Coadministration of felbamate with phenobarbital causes an increase in phenobarbital plasma concentrations, In 12 otherwise healthy male volunteers ingesting phenobarbital, the steady-state trough (Cmin) phenobarbital concentration was 14.2 micrograms/mL.
|
felbamate
|
phenobarbital
|
MECHANISM
|
Felbamate_ddi.xml
|
DDI-DrugBank.d434.s28
|
DDI-DrugBank.d434.s28.p5
|
Erythromycin has been reported to significantly alter the metabolism of nonsedating antihistamines terfenadine and astemizole when taken concomitantly.
|
Erythromycin
|
terfenadine
|
MECHANISM
|
Erythromycin_ddi.xml
|
DDI-DrugBank.d397.s10
|
DDI-DrugBank.d397.s10.p1
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
alprazolam
|
glucocorticoids
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p105
|
In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.
|
selegiline hydrochloride
|
venlafaxine
|
EFFECT
|
Dexfenfluramine_ddi.xml
|
DDI-DrugBank.d423.s0
|
DDI-DrugBank.d423.s0.p20
|
Concomitant administration of Kerlone with the oral anticoagulant warfarin has been shown not to potentiate the anticoagulant effect of warfarin.
|
warfarin
|
warfarin
|
NONE
|
Betaxolol_ddi.xml
|
DDI-DrugBank.d489.s1
|
DDI-DrugBank.d489.s1.p5
|
Anticholinergics: Concurrent administration of certain anticholinergic compounds, such as belladonna alkaloids and dicyclomine, would be expected to compromise the beneficial effects of cisapride.
|
anticholinergic compounds
|
cisapride
|
EFFECT
|
Cisapride_ddi.xml
|
DDI-DrugBank.d237.s3
|
DDI-DrugBank.d237.s3.p6
|
Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
|
estrogen-containing compounds
|
phenytoin
|
NONE
|
Levothyroxine_ddi.xml
|
DDI-DrugBank.d411.s3
|
DDI-DrugBank.d411.s3.p95
|
In addition, ketoconazole alone can inhibit adrenal corticosteroid synthesis and may cause adrenal insufficiency during corticosteroid withdrawal.
|
ketoconazole
|
corticosteroid
|
EFFECT
|
Dexamethasone_ddi.xml
|
DDI-DrugBank.d314.s23
|
DDI-DrugBank.d314.s23.p0
|
The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
|
salicylates
|
probenecid
|
NONE
|
Chlorpropamide_ddi.xml
|
DDI-DrugBank.d245.s0
|
DDI-DrugBank.d245.s0.p17
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
Tylenol
|
Invirase
|
NONE
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p112
|
Because of the increased risk of adverse reactions in patients who have been taking benzodiazepines on a regular basis, it is particularly important that physicians query patients or their guardians carefully about benzodiazepine, alcohol and sedative use as part of the history prior to any procedure in which the use of ROMAZICON is planned.
|
sedative
|
ROMAZICON
|
NONE
|
Flumazenil_ddi.xml
|
DDI-DrugBank.d234.s12
|
DDI-DrugBank.d234.s12.p9
|
In a small (n=30) combination study of ARAVA with methotrexate, a 2- to 3-fold elevation in liver enzymes was seen in 5 of 30 patients.
|
ARAVA
|
methotrexate
|
EFFECT
|
Leflunomide_ddi.xml
|
DDI-DrugBank.d41.s3
|
DDI-DrugBank.d41.s3.p0
|
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants
|
Flupenthixol
|
Monoamine oxidase inhibitors
|
INT
|
Flupenthixol_ddi.xml
|
DDI-DrugBank.d13.s0
|
DDI-DrugBank.d13.s0.p0
|
Dose adjustment of Sensipar may be required and PTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor (e.g., ketoconazole, erythromycin, itraconazole;
|
Sensipar
|
erythromycin
|
ADVISE
|
Cinacalcet_ddi.xml
|
DDI-DrugBank.d512.s7
|
DDI-DrugBank.d512.s7.p1
|
The action of colchicine is potentiated by alkalinizing agents.
|
colchicine
|
alkalinizing agents
|
MECHANISM
|
Colchicine_ddi.xml
|
DDI-DrugBank.d146.s1
|
DDI-DrugBank.d146.s1.p0
|
Both the sedative and anticholinergic effects of the major tranquilizers are also additive to those of desipramine.
|
major tranquilizers
|
desipramine
|
EFFECT
|
Desipramine_ddi.xml
|
DDI-DrugBank.d386.s24
|
DDI-DrugBank.d386.s24.p0
|
Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.
|
anesthetics
|
barbiturates
|
NONE
|
Levorphanol_ddi.xml
|
DDI-DrugBank.d257.s0
|
DDI-DrugBank.d257.s0.p57
|
Insulin: A clinical study in 6 insulin-dependent diabetic patients demonstrated no effect of EXTRANEAL on insulin absorption from the peritoneal cavity or on insulins ability to control blood glucose when insulin was administered intraperitoneally with EXTRANEAL.
|
EXTRANEAL
|
insulin
|
NONE
|
Icodextrin_ddi.xml
|
DDI-DrugBank.d501.s5
|
DDI-DrugBank.d501.s5.p7
|
Exert particular caution in combining chlorprothixene with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.
|
chlorprothixene
|
anticholinergic drugs
|
ADVISE
|
Chlorprothixene_ddi.xml
|
DDI-DrugBank.d503.s7
|
DDI-DrugBank.d503.s7.p0
|
Hypotension - Patients on Diuretic Therapy: Patients on diuretics, and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with PRINIVIL.
|
diuretics
|
PRINIVIL
|
EFFECT
|
Lisinopril_ddi.xml
|
DDI-DrugBank.d334.s0
|
DDI-DrugBank.d334.s0.p0
|
Colchicine may increase sensitivity to the CNS depressants.
|
Colchicine
|
CNS depressants
|
EFFECT
|
Colchicine_ddi.xml
|
DDI-DrugBank.d146.s2
|
DDI-DrugBank.d146.s2.p0
|
and disulfiram When amitriptyline HCl is given with anticholinergic agents or sympathomimetic drugs, including epinephrine combined with local anesthetics, close supervision and careful adjustment of dosages are required.
|
amitriptyline HCl
|
anticholinergic
|
NONE
|
Amitriptyline_ddi.xml
|
DDI-DrugBank.d99.s18
|
DDI-DrugBank.d99.s18.p5
|
Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.
|
itraconazole
|
digoxin
|
MECHANISM
|
Digoxin_ddi.xml
|
DDI-DrugBank.d450.s2
|
DDI-DrugBank.d450.s2.p37
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
phenytoin
|
ranitidine
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p1369
|
Therefore, indomethacin and diflunisal should not be used concomitantly.
|
indomethacin
|
diflunisal
|
ADVISE
|
Diflunisal_ddi.xml
|
DDI-DrugBank.d132.s22
|
DDI-DrugBank.d132.s22.p0
|
Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .
|
TARCEVA
|
nelfinavir
|
ADVISE
|
Erlotinib_ddi.xml
|
DDI-DrugBank.d456.s1
|
DDI-DrugBank.d456.s1.p6
|
Bosentan is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4, such as lovastatin and atorvastatin.
|
Bosentan
|
lovastatin
|
MECHANISM
|
Bosentan_ddi.xml
|
DDI-DrugBank.d289.s27
|
DDI-DrugBank.d289.s27.p1
|
Diuretics: Diclofenac and other NSAIDs can inhibit the activity of diuretics.
|
Diclofenac
|
diuretics
|
EFFECT
|
Diclofenac_ddi.xml
|
DDI-DrugBank.d249.s14
|
DDI-DrugBank.d249.s14.p4
|
The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide.
|
amrinone
|
anagrelide
|
EFFECT
|
Anagrelide_ddi.xml
|
DDI-DrugBank.d75.s14
|
DDI-DrugBank.d75.s14.p11
|
Nevertheless, clinical studies, as well as postmarketing observations have shown that Lodine can reduce the natriuretic effect of furosemide and thiazides in some patients.
|
Lodine
|
thiazides
|
EFFECT
|
Etodolac_ddi.xml
|
DDI-DrugBank.d219.s11
|
DDI-DrugBank.d219.s11.p1
|
Probenecid or Cimetidine: Concomitant administration of probenecid or cimetidine decreases the elimination of zalcitabine, most likely by inhibition of renal tubular secretion of zalcitabine.
|
cimetidine
|
zalcitabine
|
MECHANISM
|
Zalcitabine_ddi.xml
|
DDI-DrugBank.d263.s20
|
DDI-DrugBank.d263.s20.p12
|
Calcium channel blockers may also have an additive effect when given with TENORMIN .
|
Calcium channel blockers
|
TENORMIN
|
EFFECT
|
Atenolol_ddi.xml
|
DDI-DrugBank.d73.s2
|
DDI-DrugBank.d73.s2.p0
|
Aspirin: Concomitant administration of aspirin with valdecoxib may result in an increased risk of GI ulceration and complications compared to valdecoxib alone.
|
Aspirin
|
valdecoxib
|
NONE
|
Valdecoxib_ddi.xml
|
DDI-DrugBank.d328.s4
|
DDI-DrugBank.d328.s4.p2
|
Uricosuric Agents: Since the excretion of oxipurinol is similar to that of urate, uricosuric agents, which increase the excretion of urate, are also likely to increase the excretion of oxipurinol and thus lower the degree of inhibition of xanthine oxidase.
|
uricosuric agents
|
oxipurinol
|
MECHANISM
|
Allopurinol_ddi.xml
|
DDI-DrugBank.d413.s9
|
DDI-DrugBank.d413.s9.p5
|
Cholinesterase Inhibitors: Dipyridamole may counteract the anticholinesterase effect of cholinesterase inhibitors, thereby potentially aggravating myasthenia gravis.
|
Dipyridamole
|
cholinesterase inhibitors
|
EFFECT
|
Dipyridamole_ddi.xml
|
DDI-DrugBank.d505.s4
|
DDI-DrugBank.d505.s4.p2
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
Felbatol
|
clofibrate
|
NONE
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p468
|
Bile acid binding resins may also interfere with the absorption of oral phosphate supplements and hydrocortisone.
|
Bile acid binding resins
|
phosphate
|
MECHANISM
|
Colestipol_ddi.xml
|
DDI-DrugBank.d345.s17
|
DDI-DrugBank.d345.s17.p0
|
Methotrexate: Concomitant administration of methotrexate and some NSAIDs has been reported to reduce the clearance of methotrexate, enhancing the toxicity of methotrexate.
|
methotrexate
|
NSAIDs
|
MECHANISM
|
Ketorolac_ddi.xml
|
DDI-DrugBank.d3.s13
|
DDI-DrugBank.d3.s13.p4
|
Coadministration of esomeprazole 30 mg and diazepam, a CYP2C19 substrate, resulted in a 45% decrease in clearance of diazepam.
|
esomeprazole
|
diazepam
|
MECHANISM
|
Esomeprazole_ddi.xml
|
DDI-DrugBank.d29.s8
|
DDI-DrugBank.d29.s8.p0
|
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride
|
VIRACEPT
|
Antimycobacterial agents
|
ADVISE
|
Nelfinavir_ddi.xml
|
DDI-DrugBank.d340.s6
|
DDI-DrugBank.d340.s6.p7
|
Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
|
aminoglutethimide
|
antithyroid drugs
|
NONE
|
Levothyroxine_ddi.xml
|
DDI-DrugBank.d411.s4
|
DDI-DrugBank.d411.s4.p6
|
The concomitant use of diflunisal tablets and other NSAIDs is not recommended due to the increased possibility of gastrointestinal toxicity, with little or no increase in efficacy.
|
diflunisal
|
NSAIDs
|
EFFECT
|
Diflunisal_ddi.xml
|
DDI-DrugBank.d132.s23
|
DDI-DrugBank.d132.s23.p0
|
Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.
|
ethyl alcohol
|
scopolamine
|
NONE
|
Lorazepam_ddi.xml
|
DDI-DrugBank.d18.s1
|
DDI-DrugBank.d18.s1.p19
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
valproate
|
ziprasidone
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p1030
|
Digoxin, Methotrexate, Cyclosporine: Diclofenac, like other NSAIDs, may affect renal prostaglandins and increase the toxicity of certain drugs.
|
Cyclosporine
|
Diclofenac
|
NONE
|
Diclofenac_ddi.xml
|
DDI-DrugBank.d249.s3
|
DDI-DrugBank.d249.s3.p7
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.